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Abstract
This article provides a collaborative perspective of the discussions and conclusions from the fifth
international workshop of combined positron emission tomorgraphy (PET)/magnetic resonance
imaging (MRI) that was held in Tübingen, Germany, from February 15 to 19, 2016. Specifically,
Correspondence to: T. Beyer; e-mail: thomas.beyer@meduniwien.ac.at
we summarise the second part of the workshop made up of invited presentations from active
researchers in the field of PET/MRI and associated fields augmented by round table discussions
and dialogue boards with specific topics. This year, this included practical advice as to possible
approaches to moving PET/MRI into clinical routine, the use of PET/MRI in brain receptor
imaging, in assessing cardiovascular diseases, cancer, infection, and inflammatory diseases. To
address perceived challenges still remaining to innovatively integrate PET and MRI system
technologies, a dedicated round table session brought together key representatives from
industry and academia who were engaged with either the conceptualisation or early adoption of
hybrid PET/MRI systems. Discussions during the workshop highlighted that emerging unique
applications of PET/MRI such as the ability to provide multi-parametric quantitative and visual
information which will enable not only overall disease detection but also disease characterisation
would eventually be regarded as compelling arguments for the adoption of PET/MR. However,
as indicated by previous workshops, evidence in favour of this observation is only growing
slowly, mainly due to the ongoing inability to pool data cohorts from independent trials as well as
different systems and sites. The participants emphasised that moving from status quo to status
go entails the need to adopt standardised imaging procedures and the readiness to act together
prospectively across multiple PET/MRI sites and vendors.
Key words: PET/MRI, Combined imaging, Molecular imaging, PET/CT, PET, MRI, Quantifica-
tion, Attenuation correction, Oncology, Neurology, Cardiology, Multi-parametric imaging
Introduction
This paper summarises discussions at the 2016 international
positron emission tomography (PET)/magnetic resonance
Imaging (MRI) workshop held in Tübingen, Germany. This
is the fifth consecutive year that the faculty of the Eberhard-
Karls-Universität and the Universitäts Klinikum Tübingen
have jointly hosted this workshop, which is now firmly
established as the most influential, vendor-independent
international meeting to focus on the emerging applications
and technological challenges of PET/MRI. This year, the
workshop and meeting was attended by over 120 delegates
from more than 20 countries, 50 % of whom came from
outside Europe. Industry was also well represented with
invited talks from the majority of the vendors involved in
developing the hardware and software for PET/MRI.
One notable feature of the 2016 workshop was that there
were more discussions on non-oncological applications of
PET/MRI than in previous years. New areas of application
that were addressed included inflammation and infection,
cardiovascular applications, beta-cell function and mass in
diabetes, neurotransmitters, radiomics, and tracking of
radiolabelled cells. There are now over 100 PET/MRI
systems worldwide either being operated or installed, a third
of which were acquired in the last year. This growth rate
should, of itself, broaden the range of applications which are
investigated with PET/MRI.
The previous workshop suggested that PET/MRI with 2-
deoxy-2-[18F]fluoro-D-glucose (FDG) should not try to
compete with or replace [18F]FDG-PET/X-ray computed
tomorgraphy (CT) in many oncological applications [1]. A
role for [18F]FDG-PET/MRI was envisaged in paediatric
oncology and for patients of reproductive potential to
minimise exposure to ionising radiation from the CT
component of a PET/CT study. Beyond this, however, it
was thought that the most potentially productive areas for
PET/MRI would be with non-[18F]FDG radiopharmaceuti-
cals. A question was raised as to whether PET/MRI could be
envisaged as the only PET system available in a facility, and
most attendees agreed that it should not; the first choice,
especially for oncological applications, would remain PET/
CT mainly because of the shorter examination times and,
secondly, because of easier interpretation by nuclear medi-
cine physicians.
Participants at the meeting emphasised that a close
collaboration between radiologists and nuclear medicine
physicians helps the optimisation of acquisition protocols
based on a deep knowledge of advanced MRI techniques.
Naturally, patients with contraindications for undergoing an
MRI scan may still require a PET/CT if a PET scan is
indicated. The high cost of PET/MRI as compared to PET/
CT was considered a major factor influencing the choice of
imaging method, particularly in public and governmental
institutions.
Each of the previous workshops has attempted to address
the question as to what might be a key application for PET/
MRI. This year, for the first time, prostate cancer imaging
with [68Ga]PSMA has emerged as a tangible key application
for PET/MRI. Of note, this was largely uncontested by those
currently using PET/CT for this application.
As in previous summary reports, we attempt to provide
succinct individual topic summaries and indicate major
outcomes of the discussion boards. Likewise, we highlight
progress achieved and comment on areas where only limited
advances have been made. Finally, we will adhere again to
the general conventions of previous reports to indicate
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progress (↑), steady state (↔) and regression (↓) in key
aspects of PET/MRI. The key to the summary tables of
changes in PET/MRI with respect to the status of the
previous year is shown below.
↑ Documented evidence of improvement in science and methodology
↗ Suggestion of improvement in methodology but requires further
investigation
↔ No change but satisfactory status since previous workshop
↘ Little advancement in science and methodology despite previous
recognition of need for improvement
↓ Less clear evidence than previously suggested
This year, the workshop commenced with discussion of
two topics which are uppermost in the mind of many
involved in the field, namely, BHow to move PET/MRI into
clinical routine^ and BFrom status quo to status go in PET/
MRI^.
Discussion: How to Move PET/MRI
into Clinical Routine
Since the introduction of combined, whole-body PET/MRI
users have searched for the key clinical application [1–4].
This search has been conducted mainly by single institutions
(rather than networks or by pooling data), and evidence in
favour of, or against, identifying a specific indication as a
key application has been weak. The topic of this opening
session was chosen deliberately to tune in to recent
scepticism regarding a broader role of combined PET/MRI
in clinical routine [5, 6].
The speakers in the opening session were drawn both from
private practice and from a university-based hospital, i.e. both
with a strong interest in clinical PET/MRI (as opposed to
research only). Some of the reasons given for the slow
translation of PET/MRI into routine clinical practice included
a general lack of guidelines and standardisation for the use of
PET/MRI, ongoing lack of supporting evidence for potential
clinical applications of PET/MRI, lack of protocol optimisation
and advanced analysis software from collaborations between
vendors and users, and unresolved issues relating to which
professional groups should perform and report the scans. In an
attempt to address some of these requirements, the Japanese
Radiologic Society, the Japanese Society of Nuclear Medicine,
and the Japanese Society of Magnetic Resonance Imaging have
recently joined to produce a set of on-line guidelines for the use
of PET/MRI [7].
At previous workshops there had been much discussion
about the most appropriate MRI sequences to acquire in
PET/MRI examinations [1, 4] and to try and reduce this
number from what was desirable to what is sufficient. The
protocols presented in this session for routine examinations
have been optimised such that the total scan time has been
minimised (Tables 1 and 2). In practice, it was reported that
a five-bed position scan can be completed in 50–60 min
while an extended nine-bed position scan (∼2 m axial extent)
could take up to 90 min. Total running costs for operating a
PET/MRI in Germany were estimated at approximately
100,000€ per calendar month. This presents a challenging
business model in the absence of a satisfactory reimburse-
ment scheme, as is currently the case in Germany.
Other oncological applications that were suggested to
have potential clinical application in the future using PET/
MRI included breast cancer (where CT has virtually no role),
prostate cancer (where multi-parametric MRI is extremely
valuable [8–10]), colorectal carcinoma (where MRI was felt
to have an advantage in detecting nodal involvement),
melanoma (both for whole body and for brain), gynae
cological cancers (specifically addressing the issue of loco-
regional recurrence), and brain tumours (where CT contrib-
utes little); however, evidence to support these speculations
does not currently exist.
A proposed variation on the existing protocol illustrated
in Table 1 that was proposed was to begin the MRI
acquisition during the uptake phase of the PET radiotracer,
which is typically 60 min for [18F]FDG. While this would
not reduce the total duration of imaging in the PET/MRI
system, it would reduce the time that the subject was
required to attend the clinic. An alternative protocol was
proposed by a different experienced PET/MRI site to bring
down overall image acquisition time to a length equivalent
to that of a whole-body PET/CT (Table 2).
Discussion: from Status Quo to Status
Go in PET/MRI
While the previously reported session focussed on the
potential clinical applications of PET/MRI (i.e. beyond
research applications), this session focussed on what was
required to move PET/MRI, into a role where the unique
information that it enables can be integrated into routine
practice and fully exploited. It was suggested that PET/CT
could appropriately be described as Banatomically enhanced
molecular imaging^. PET/MRI would need to provide more
than this to justify its higher capital costs and reduced patient
throughput compared to PET/CT. There was further discus-
sion about the total length of the imaging protocol and the
need for the vendors and users to work more closely in an
effort to reduce this to the minimum possible, while still
retaining the ability to better characterise tissue and
pathologies than is possible with X-ray CT. Also echoing
sentiments from the first session, it was felt that there was a
need to identify where PET/MRI had an advantage over
PET/CT studies (Table 3).
Triaging patients to PET/CT or PET/MR, as it is done at
one site by following the separation scheme laid out in
Table 3, automatically leads to a discussion about whether
PET/CT and PET/MRI should be considered as competing
or complementary. Much of the initial work with PET/MRI
was to establish whether it provided equivalent information
to PET/CT in the more common indications. Many would
argue that for the majority of the time PET/MRI probably
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does provide this. However, in most published work to date,
the question of a complementary role was not one that has
been given the same attention as the competitive role of the
combined imaging modalities.
An example of how the complementary nature could be
exploited would be for a PET/MRI examination to
immediately follow a standard PET/CT procedure in
selected patients, with the imaging objective being
restricted to limited region of the body. The properties of
the tissue encompassed by this volume would be more
accurately characterised with multiple MRI sequences in
combination with the radiotracer distribution obtained with
PET/CT [11]. One scenario where this might be indicated
could be intra-tumoural heterogeneity observed by PET
with PET/CT imaging without the CT image being able to
provide any further ability to characterise the tissue in
question. A follow-on PET/MRI scan could focus on the
lesion in question in a limited, regional PET/MRI inves-
tigation, which could be relatively rapid, but still provide
useful information (e.g. diffusion coefficient, and oedema)
about the tumour environment based on spatial character-
isation from different sequences. However, the logistics of
such an operation may be challenging.
Panellists also tried to put PET/MRI into the context of a
wider spectrum of diagnostic techniques as related to future
investigations in human disease. It was emphasised how the
cost of genetic sequencing was decreasing rapidly, while the
costs of many new therapies were increasing. A common
theme was that Bimaging needs to perform better than
biopsy-based diagnosis^. The use of liquid biopsies (serum,
urine) is increasing (e.g. transcriptomes and circulating
DNA) and is likely to provide earlier information about
disease status, recurrence, and progression. The unique role
for imaging in this scenario will be to provide whole-body or
regional information complementary to the biopsy or blood
sample. To enhance this capability of the PET/MRI will
require developments in multi-parametric imaging, advanced
image analysis, and linking imaging to proteomics, metabo-
lomics, and genomics. Each of these areas implies an
expanded role for data mining and radiomics [12] to which
PET/MRI is naturally suited. Finally, these advances need to
be translated into clinical practice.
In summary, the opening sessions emphasised the
following requirements for PET/MRI to move into main-
stream clinical practice:
 Optimisation of PET/MRI protocols to achieve a balance
between an abundance of image-based information and
realising this in a practical imaging protocol (total
examination time ≤45 min)
 Collaboration between the vendors and the users to achieve
optimised acquisition protocols and software for analysis
 The development of specific guidelines for PET/MRI
investigations
 Development of a suitable evidence base for the
appropriate use of PET/MRI using appropriately designed
Table 1. Example generic timeline for a PET/MRI oncological Bwhole-body^ examination. Note that the PET acquisitions (6 min each) are approximately
two to three times longer than for current PET/CT investigations, therefore, allowing for either a reduction in the amount of radiopharmaceutical administered
or enhanced image quality using a standard amount administered (data courtesy of M.Lentschig, Bremen
Elapsed time [min)( PET exam MRI exam MRI details
0–2 Fast view scout
3–4 Planning exam
5–10 Pos1—pelvis Pos1—pelvis AC (DIXON) 19 s T2w HASTE 42 s DWI 120 s T2w TRIM 150 s
11–12 Auto shim/breath hold
13–18 Pos2—abdomen Pos2—abdomen AC (DIXON) 19 s T2w HASTE 42 s DWI 120 s T2w TRIM 150 s
19–20 Auto shim/breath hold
21–26 Pos3—thorax Pos3—thorax AC (DIXON) 19 s T2w HASTE 42 s DWI 120 s T2w TRIM 150 s
27–28 Auto shim/breath hold
29–34 Pos4—neck Pos4—neck AC (DIXON) 19 s T2w HASTE 42 s DWI 120 s T2w TRIM 150 s
35–36 Auto shim/breath hold
37–42 Pos5—head Pos5—head AC (DIXON) 19 s T2w HASTE 42 s DWI 120 s T2w TRIM 150 s
43 Auto shim/breath hold
44–47 Head-to-pelvis pre-contrast T1 VIBE
48–50 Liver 4× T1 VIBE
51–54 Head-to-pelvis post-contrast T1 VIBE
Table 2. Example timeline of a Bfast protocol^ for a whole-body PET/MRI for oncological indications. The total acquisition comprises four bed positions of
4-min emission time each and a post-contrast whole-body VIBE sequence (no PET), resulting in a total examination time on the order of that for a whole-body
PET/CT scan (∼18 min) (data courtesy of L. Umutlu, Essen)
PET (min:s) 4:00 4:00 4:00 4:00 1:36
Anatomical region Pelvis Abdomen Thorax Head/neck Whole body
MRI details AC
HASTE (axial)
DWI
AC
HASTE (axial)
DWI
AC
HASTE (axial)
DWI
AC
HASTE (axial)
DWI
T1w VIBE
+ Gd-contrast
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trials acceptable to regulators and health technology
agencies
 Exploitation of added clinical value combining multi-
parametric PET/MRI data with multi-scale clinical,
laboratory, histopathologic, and B–omics^ data
Dialogue Board 1: Neurosciences
The Issues
Brain disorders are reported to cost more than $US1
trillion ($US1 × 1012) p.a. This is greater than the amount
spent on cancer, cardiovascular disease, and diabetes
combined [13]. PET occupies a unique role with its ability
to non-invasively probe neurotransmitter systems with
radiolabelled exogenous and endogenous molecules in a
way that other modalities are unlikely to match in vivo.
MRI provides new information about brain circuitry with
the use of connectivity analysis for both structural and
functional information. The combination of studying
disrupted neurotransmitter pathways with PET and the
downstream implications on connections within brain
circuits therefore offers a potentially powerful paradigm.
Examples include the interaction between dopamine re-
lease and executive function and the prediction of drug
response using changes in extracellular serotonin on
functional MRI (fMRI) and PET. Of particular interest
will be studies that investigate the correlation between
neurotransmitter release and brain networks that are
activated in response to external stimuli. These studies
require that the PET and MRI acquisitions be performed
simultaneously. Such stimuli can be either pharmacological
or, perhaps more importantly, habituation-dependent tasks
with their novelty decreasing as the task is repeated or
evoke a non-fully reproducible response (e.g. response to
pain). The determination of such correlations is relevant to
improve our understanding of diseases such as addiction,
schizophrenia, or neurodegeneration.
Recent Advances or Achievements
There has been a continuous, increasing focus on the role
of PET/MRI in psychiatric disorders. In particular, the
serotonergic system has been receiving greater attention
given the fact that a number of highly selective and
specific radioligands are available for the quantification of
major receptors, transporters, and enzymes of this system.
Examples of the uses for PET/MRI in this domain include
(i) prediction of drug response using serotonergic radio-
tracers (drug occupancy, pharmacological interaction with
fMRI, and hormonal interactions with brain function) and
frequently prescribed antidepressants as selective serotonin
reuptake inhibitors, (ii) the combination of PET +MRI +
EEG to combine higher spatial and temporal resolution
measurements, and (iii) the introduction of α4β2 choliner-
gic receptor radioligands [14]. Recent studies have also
shown that dopamine agonists and antagonists induce
opposite effects on cerebral blood flow providing impor-
tant insights into neurovascular coupling [15, 16].
New Evidence That Has Been Reported
A number of studies have now shown that the accuracy of
PET image reconstruction from PET/MRI acquisitions
using currently available methods for photon attenuation
correction is acceptable. Previously, this was seen as a
remaining barrier to more widespread introduction of PET/
MRI brain studies. Today, the attenuation correction issue
discussed in recent workshops [1] appears readily solved in
the case of [18F]FDG brain imaging [17–19] and hence
should be acceptable for neurotransmitter studies as the
extended MRI sequences that can be used are compatible
Table 3. List of PET/MRI and PET/CT preferred clinical indications as adopted at a long-standing PET/MRI site in Germany (adapted from Stephan Nekolla,
Nuklearmedizinische Klinik der TU München, Germany)
Scan indication PET/CT PET/MRI
Neuroimaging
Neurodegenerative disease or where MRI is standard of care – ✓
Dynamic PET scans required – ✓
MRI exclusion criteria met (valves, pacemakers, claustrophobia) ✓ –
Oncological Imaging
Prostate primary staging, recurrence ✓ –
Prostate biopsy planning – ✓
Prostate therapy ✓ –
Focus on liver – ✓
Focus on lung ✓ –
Paediatric imaging – ✓
MRI exclusion criteria met ✓ –
Problems lying supine for 930 min ✓ –
Cardiac imaging
MRI exclusion criteria met ✓ –
All others – ✓
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with dynamic, temporal data acquisition with PET in a
single bed position. In addition, the morphological imaging
from MRI can be used to define intra-cerebral arteries
where the profile of the arterial blood input signal can be
determined for use in kinetic models of PET radioligands,
if suitable corrections for tracer metabolites, when needed,
can be devised.
New evidence on PET image reconstruction using time-
of-flight (ToF) information to further improve the accuracy
of attenuation correction appears to be promising [20–23].
In parallel to the neuroreceptor PET imaging procedure,
information on neurodegeneration can be obtained from
concomitant arterial spin labelling MRI [24] and voxel-
based morphometry of anatomical MRI data [25]. Overall
progress indicators for PET/MRI in neurology are given in
Table 4.
Future Challenges
A major technical hurdle during complex neuroimaging
protocols is the limited ability to integrate multiple datasets
into appropriate kinetic and neural models. An appropriate
framework is needed for the quantitative combination of
parameters from different modalities, and it is hoped that
field of radiomics can offer additional insights and
support.
One advantageous feature of integrated PET/MRI is the
possibility of on-line movement correction of the acquired
PET data by MRI-based movement detection [26]. In the
field of neuroreceptor studies, this technological gain
should be tested for its potential improvement of dopami-
nergic imaging in movement disorders, like Parkinson’s
disease. Future neuroreceptor PET/MRI research activities
should also involve studying the opioid system and its
effect on brain haemodynamics, e.g. in pain disorders [27],
as well as proof-of-concept studies on neurotransmitter
drug testing.
One challenge for simultaneous dynamic imaging arises
from the different temporal resolution of PET and fMRI
and the fact that kinetic modelling using dynamic PET data
usually assumes a steady-state situation, whereas MRI can
be used to study evoked responses over a short time frame
(e.g. BOLD technique). However, recent studies demon-
strated promising new applications of simultaneous mea-
surements of fMRI and fPET with a timing resolution of
minutes in both methods, thus comparing tasks that have
been classically restricted to fMRI or ASL [28–30]. Thus,
t he compa r i son of func t i ona l and molecu l a r
Bconnectomes^ of the human brain now seems to be
within reach with PET/MRI.
Finally, more advanced PET data analysis methods
such as for neurotransmitter PET will need to be further
developed to fully exploit multi-parameter information
provided by PET/MRI [31, 32].
Dialogue Board 2: Cardiovascular
Diseases
The Issues
The previous year’s workshop proposed that cardiovascu-
lar PET/MRI studies would develop a significant clinical
role by combining pre-existing examinations already
carried out on separate PET and MRI systems into one
convenient examination [1]. However, at this workshop,
the presenters focussed more on identifying new areas of
application for PET/MRI where studies on either stand-
alone PET or MRI were not likely to answer the clinical
question, and hence PET/MRI would provide unique
information. In this regard, the move from the research
domain to the clinic has not progressed as anticipated, with
new areas of application (as discussed below) still being
investigated. Areas that were discussed included imaging
inflammation in both the vessel wall (plaque imaging) and
the myocardium, and imaging of cardiac innervation. For
vascular imaging, MRI is currently accepted as the gold
standard for the whole-body characterisation of the arterial
vessel wall in determining the presence, size, and type of
atherosclerotic plaques. However, the addition of PET
should help to further identify the vulnerable plaque [33].
For myocardial tissue characterisation, quantitative T1
mapping was also discussed as a surrogate marker of
therapeutic response and outcome in diffuse myocardial
processes such as post-infarction fibrosis or in cardiomy-
opathies or storage diseases [34, 35]. PET measurements
may supplement these in identifying areas of acute
inflammation and identifying metabolic changes using
[18F]FDG.
Recent Advances or Achievements
Although there is a clear vision for a unique application of
PET/MRI in cardiovascular imaging [36], recent advances
have been few. This can be explained in part by the technical
challenges of imaging small and moving structures, such as
Table 4. Progress indicators for PET/MRI in neurology
2012 2013 2014 2015 2016
Improved understanding of brain physiology and function through the use of combined PET/MRI ↔ ↗ ↗ ↗ ↗
Methodological progress for improved quantification of PET/MRI neurological examinations (AC, IDIF, SUV) ↔ ↔ ↗ ↗ ↗
MR-based motion correction for routine clinical use ↓ ↘ ↔ ↔ ↔
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the arterial vessel wall and the myocardium. To address
some of these challenges, current research has been focused
on MRI-based cardiac and respiratory motion compensation
to improve both MRI and PET image qualities as well as
PET-based quantification [37]. The following list of tracers
were considered to be of potential interest for clinical cardiac
PET imaging in combination with MRI:
 [18F]NaF for imaging vulnerable plaque
 [64Cu]DOTA-Octreotate for imaging macrophages
 [68Ga]Pentixafor for imaging CXCR4 expression in
inflammation
 [18F]BR351 for imaging of matrix metalloprotease activ-
ity in inflammation
 [18F]FDG-labelled leucocytes for imaging inflammation
 [18F]LMI1195 for imaging cardiac innervation
New Evidence That Has Been Reported
PET/MRI has been mainly used in combination with [18F]FDG
to identify and characterise vascular inflammation in the carotid
artery [38, 39]. In general, these studies focussed on protocol
development, the feasibility of the integrated PET/MRI ap-
proach, and quantification issues. First studies have been
described to integrate PET imaging of innervation with
structural and functional MRI imaging for the characterisation
of post-infarct myocardium [40] (Table 5). PET/MRI imaging of
(vulnerable) plaque in the coronary arteries, even though
clinically desirable, still suffers from limited robustness of
MRI for this specific application, thus limiting a broader clinical
implementation of dedicated PET/MRI protocols for coronary
inflammation and atherosclerosis [41].
Combined [18F]FDG PET/MRI early after myocardial
infarction following successful intervention revealed a high
predictive value for the assessment of inflammatory tissue
state during adverse remodelling of the left ventricle [42]. In
addition, novel tracers targeting these processes more
specifically are becoming available [43]. These strategies
have the potential to optimise patient-specific medical
interventions and also to prospectively assess novel therapies
using quantitative measures.
Future Challenges
The panellists suggested that some of the remaining
technical challenges for PET/MRI included the reduction
of truncation artefacts, the incorporation of respiratory and
cardiac motion compensation, the shortening of the lengthy
acquisitions, the development of radiopharmaceuticals that
maximise the plaque-to-blood contrast in the vascular
system, and the quantification of MRI signals.
In spite of the prediction of the previous year’s workshop
regarding the clinical role of PET/MRI in cardiovascular
imaging, attendees conceded that at this stage cardiovascular
PET/MRI was still a research tool. This reflection was
partially based on the fact that most of the processes in
cardiovascular disease (atherosclerosis, myocardial infarc-
tion and cardiomyopathies) can be described only to a
limited extent through animal models.
Dialogue Board 3: Oncology
The Issues
Oncological imaging with [18F]FDG has been the focus of
PET/MRI since its inception, largely based on the success of
PET/CT in this area. The view that has emerged from the
Tübingen workshops over the preceding years is that the
future of PET/MRI is in areas of oncology where PET/CT
currently has little or no role. Examples include cancers of
the breast, prostate, pancreas, and some indications for
imaging the liver. It was proposed that combined multi-
modality imaging could provide three general types of data:
(i) Complementary information
(ii) Confirmatory information
(iii) Redundant information
In this context, PET/MRI could be considered to be a single
modality (neither PET-only nor MR-only), thereby assuming
more and more the role of a "problem solving" tool. Reviewing
five years of PET/MRI in oncology, panellists concluded that
PET/MRI performed equally well as PET/CT in many areas [6]
but at the cost of increasing infrastructure needs and longer
acquisition times. In paediatric imaging, in particular, no clear
diagnostic superiority of PET/MRI over PET/CT has been
demonstrated to date, however, the studies can be performed
with a significantly reduced radiation exposure.
Recent Advances or Achievements
One area where it appears that PET/MRI has now
demonstrated superior diagnostic performance to PET/CT
Table 5. Progress indicators for PET/MRI in cardiovascular diseases (CVD)
2012 2013 2014 2015 2016
Resolution of methodological issues for CVD imaging (MR-AC, motion correction) NA ↗ ↗ ↔ ↔
Develop analysis tools for standard CVD applications NA ↔ ↔ ↔ ↔
Identification of key parameters/biomarkers from PET and MRI to avoid redundancy in PET/MRI data NA ↔ ↗ ↗ ↗
Standardised imaging protocols NA ↔ ↔ ↔ ↘
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in oncology is in prostate cancer [68Ga]-PSMA imaging
[44]. There was a notable increased degree of discussion at
this workshop on the role for loco-regional PET/MRI,
potentially using previous imaging to direct the PET/MRI
to a particular region of the body for a more thorough
characterisation. It was noted by one of the panellists that, if
this approach (i.e. regional PET/MRI) were implemented, it
could be achieved with a significantly reduced radiation
exposure from the PET study by reducing the amount of
radiotracer administered, as the MRI sequences would be the
rate-limiting step while the PET was acquired simulta-
neously over a longer period than usual. Specifically, in
standard TOF-PET/MRI, clinical [18F]FDG doses can be
lowered by 40–50 % compared to standard TOF-PET/CT
while maintaining equivalent image quality [45]. One
potential example for single station imaging with PET/MRI
and ultra-low radiotracer doses administered would be breast
imaging. Here, effective patient exposure from the combined
examination of around 1 mSv appears achievable. With such
indications, PET/MRI could be opened up for a wider field
of clinical oncological indications (Table 6).
New Evidence That Has Been Reported
Since the last meeting, there have been further published
studies of the diagnostic potential of PET/MRI in cancers of
the cervix [46], endometrium [47], colorectal [48], breast
[49], head and neck [50], and thyroid and metastatic prostate
disease [51] in comparison to PET/CT and for response
prediction in gastric cancer [52]. However, the number of
patients studied remains relatively small.
Future Challenges
The challenge remains to define areas of clinical applica-
tion where combined PET/MRI will provide new and
unique information. Prostate cancer imaging or the reduc-
tion of radiation dose alone was thought unlikely to justify
the cost of PET/MRI for most users. An important
challenge to be addressed was the need to simplify MRI
acquisition protocols to avoid sequences that provide no
incremental value to that already provided by PET, thus,
focussing rather on selecting sequences that provide
superior information than that provided by the CT
component of PET/CT.
Dialogue Board 4: Infection
and Inflammation
The Issues
This was a new topic introduced for the first time at this
workshop. Nuclear medicine imaging has had a long
history of infection imaging using agents such as
[67Ga]citrate, radiolabelled white blood cells (WBCs),
[111In]Oxine, bacterial imaging agents, and [18F]FDG. In
sterile inflammatory processes, a large number of potential
targets exist that may be amenable to imaging such as
GLUT, TSPO, SSTR, COX, MMP, CB2R, FPR, CD20,
CD25 (IL-2R), TNFR, VCAM-1, VAP-1, and α2β3 [53].
The proposed advantages of PET/MRI for imaging
infection and inflammation include the ability to image
the whole body, and to use the PET, in particular, to
identify the most active areas for further MRI characteri-
sation. Alternatively, a whole-body PET/CT study can be
considered the method of choice for searching for an
infective focus or disseminated foci followed by a loco-
regional PET/MRI imaging procedure of the respective
areas of interest, as promoted in a similar fashion in the
Dialogue Board on oncology.
Some of the potential clinical areas of application named
for combined PET/MRI included soft tissue inflammation,
GI inflammation (inflammatory bowel disease) [54, 55],
cardiovascular processes such as acute myocarditis and
sarcoidosis, rheumatoid arthritis [56], type-1-diabetes [57],
giant cell arteritis, and spondylodiscitis [58]. It was noted
that, yet again, CXCR4 and CD25 are expressed on most
infiltrating cells in many of these processes and hence
provide a PET target.
Recent Advances or Achievements
This is an emerging area and hence clinical data to support
this application area still being investigated (Table 7).
Table 6. Progress indicators for PET/MRI in oncology, including paediatric imaging
2012 2013 2014 2015 2016
Definition of key clinical applications ↔ ↔ ↗ ↗ ↗
Diagnostic quality of PET in PET/MRI equivalent to PET quality in PET/CT ↔ ↔ ↗ ↗ ↗
Resolving quantitative bias from MR-AC ↘ ↔ ↔ ↔ ↗
Clinical data available on diagnostic accuracy of PET(/MRI) in oncology ↔ ↔ ↗ ↔ ↗
PET/MRI protocol standardisation ↓ ↔ ↘ ↔ ↔
Clinical evidence on the usefulness of PET/MRI in paediatric oncology ↔ ↗ ↗ ↗ ↔
Reduced radiation exposure as a key driver for PET/MRI of children ↗ ↑ ↑ ↔ ↘
Initial results of a complementary role of advanced MRI techniques for restaging of lymphoma patients ↔ ↔ ↗ ↔ ↔
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New Evidence That Has Been Reported
Recent insight into the role of PET/MRI in inflammation has
been published [53]. Some centres already use [18F]FDG-
PET/CT for inflammation/infection imaging although in
most cases standardised image interpretation criteria are
absent [58].
Future Challenges
The panellists concurred that cell labelling and tracking
using PET would be extremely helpful in these application
areas. This implies the use of radionuclides with longer
half-lives than the main ones currently used (F-18, C-11,
Ga-68). Candidates that potentially fulfil this requirement
include Cu-64, Zr-89 and I-124 providing these will not
modify cell viability or function. Alternatively, new
peptides and/or cytokines labelled with conventional PET
short half-life radionuclides might allow us to target cells
in different clinical situations [59–61]. This suggestion
may foreshadow the need for an increase in future
radiopharmaceutical production.
Dialogue Board 5: Emerging Areas
The Issues
The second new session was dedicated to emerging areas
that may have synergy with PET/MRI. In the introduction to
the session the audience was reminded that PET/MRI users
must be Bmore than just photographers^, implying that
PET/MRI should provide a deeper characterisation of the
physiological processes involved and not just be used to
identify sites of disease (e.g. Bhot spot localisation^). The
two areas chosen for focus in this session were the emerging
field of radiomics and the role of PET/MRI in pancreatic β-
cell imaging and diabetes.
Recent Advances or Achievements
Radiomics refers to Bthe extraction and analysis of large
amounts of advanced quantitative imaging features with high
throughput from medical images obtained with computed
tomography, positron emission tomography or magnetic
resonance imaging^ [62]. It is based on the proposition that
Bimages are more than pictures; they are data^ [12]. PET/
MRI provides an extremely useful platform for radiomics
development based on multi-modality imaging from a large
number of complementary signals. PET/CT, in contrast,
would be restricted to essentially two components only, the
PET signal and the CT morphology, whereas MRI is able to
provide a multiplicity of sequences that can probe different
aspects of the tissue micro-environment. An example of a
potential new target was carbonic anhydrase 9 (CA-IX) and
its increased expression at the advancing edge of cancerous
tissues [63, 64].
Secondly, in this session, the discussion turned to
studying the pancreas with PET/MRI. The emerging burden
of diabetes in developed societies is often referred to as an
epidemic. PET/MRI should be an ideal tool to study a
metabolic disorder such as diabetes. In recent years,
evidence has been growing that beta cell loss is not the sole
and leading pathophysiological process in the pancreas that
finally leads to insufficient production of insulin. Instead,
loss of the capacity of the beta cells to produce and release
insulin appears to play a more important role, caused by or
preceding de-/trans-differentiation and apoptosis. Measuring
and following beta cell mass in relation to beta cell function
(i.e. insulin production, storage capacity, and release) during
the course of the disease and in response to treatments would
therefore be a major asset in diabetes research [65, 66]. Data
were presented to indicate that PET/MRI can measure both
β-cell mass and β-cell function, using manganese contrast
MRI for function (namely insulin release) and
[68Ga]Exendin to assess the mass [65, 67].
New Evidence That Has Been Reported
Both areas are at the cutting edge of developments and may
benefit from PET/MRI studies in the future (Table 8). While
radiomics has mostly been applied to cancer to date this may
be extended into other areas with PET/MRI, and the field of
diabetes and metabolism is essentially a new focus for
imaging with PET/MRI. Both methods rely on quantitative
imaging approaches.
Future Challenges
Data management will be a challenge when combining the
large number of signals produced by PET/MRI over millions
of voxels in the case of whole-body studies. Robust
statistical techniques will be required to extract essential
Table 7. Progress indicators for PET/MRI in infection and inflammation imaging
2012 2013 2014 2015 2016
Improved tissue characterisation by combined PET/MRI – – – – ↗
Development of new radiopharmaceuticals for PET use in general – – – – ↗
Standardised imaging protocols – – – – ↔
Standardised image interpretation criteria – – – – ↔
Definition of key clinical applications – – – – ↗
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information and protect against type I errors. In addition,
individuals with skills that are able to span the biological to
the statistical and imaging fields will need to be recruited,
trained, and retained.
It is becoming increasingly apparent that minor gains in
diagnostic accuracy, or even significant improvements in
this regard, will be insufficient alone to ensure reimburse-
ment of new imaging techniques, particularly if these add
significantly to the cost of diagnosis. Adding an expensive
imaging modality, like PET/MRI, to existing imaging
paradigms is likely to face significant hurdles purely on
economic grounds. Therefore, the design of novel diagnostic
approaches, which provide superior diagnosis at comparable
cost or that improve allocation of expensive therapies, is
required. Most trials of new imaging modalities have
focussed on demonstrating the incremental diagnostic
information after conventional imaging tests have been
performed. If the cost of the technique is high and the
diagnostic gains are small, cost effectiveness is unlikely.
An alternative approach is to address the independent
diagnostic value of doing the more accurate but more
expensive test instead of conventional imaging and offset-
ting any differential cost by savings in avoidance of
additional investigations or inappropriate therapeutic inter-
ventions. A randomised crossover design has been devel-
oped by researchers at the Peter MacCallum Cancer Centre
in Australia to compare conventional and experimental
imaging paradigms for independent and incremental utility
(Fig. 1). By randomly assigning patients to either conven-
tional or experimental imaging, the independent diagnostic
utility is defined by those cases in which the definitive
management plan is decided upon by the initial test
performed. For example, if the primary test indicates
systemic metastasis and excludes all loco-regional therapies
and mandates systemic therapy, the patient would not
crossover. Alternatively, unless there is a definitive exclu-
sion of alternative therapies on the basis of this scan, the
patient would crossover to the alternative paradigm. Incre-
mental diagnostic information is defined by a change in final
management plan on the basis of the second study. If the
management decision remains unchanged, the study is
defined as having no impact. By contrast, if the second
investigation changes treatment intent or modality (high
impact), or delivery of a previously planned therapeutic
modality without change in treatment intent (medium
impact), an incremental value is demonstrated.
Table 8. Multi-parametric imaging and emerging areas
2012 2013 2014 2015 2016
Fully integrated PET/MRI exclusively offers the largest variety of multi-parametric biomarkers ↔ ↗ ↑ ↑ ↑
Validation of advanced multi-parametric biomarkers in clinical research (beyond Bimage fusion^) ↘ ↔ ↗ ↗ ↔
Contributions of small animal imaging to the understanding of multi-parametric biomarkers ↔ ↗ ↑ ↑ ↗
Using standardised approaches for assessing the accuracy of PET/MRI and towards multi-parametric image
analysis
– – – ↗ ↔
Fig. 1 Flow diagram of proposed randomised control trial (RCT) for evaluating novel imaging paradigms. Rather than
demonstrating incremental value from single-injection, dual-imaging PET/CT-PET/MRI comparisons, an added value needs to
be assessed from a management plan implementation (courtesy of R Hicks, Peter Mac Cancer Centre Melbourne, Australia).
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It should be noted that almost all imaging studies look
at the incremental value of new tests by applying them in a
subgroup of patients based on eligibility criteria defined by
conventional imaging. This methodology was first utilised
to assess the incremental utility of PET imaging in patients
with lung cancer who had no definite evidence of
metastatic disease on conventional imaging [68, 69] and
was subsequently adopted by the National Oncological
PET Registry (NOPR) [70], which led to wider reimburse-
ment of PET and PET/CT. In the proposed study design,
the appropriateness of the final decision is validated by a
composite measure of accuracy determined from the
Fig. 2 Poll results from fifth PET/MRI workshop participants: a What do you think will be the main application for PET/MRI
(select up to three)? b Who should read PET/MRI examinations in clinical practice? and c What are the greatest barrier to
bringing PET/MRI to the clinic (select up to three)? (questions courtesy of Dr Sarah Bond, Mirada Medical, UK).
Table 9. Progress indicators for key applications for PET/MRI
2012 2013 2014 2015 2016
Paediatric oncology is a key application of PET/MRI ↗ ↗ ↑ ↑ ↘
Dementia is a key application of PET/MRI ↗ ↑ ↑ ↑ ↗
Neuro-Oncology is a key application of PET/MRI ↗ ↗ ↗ ↔ ↔
Cardiovascular imaging is a key application of PET/MRI ↔ ↔ ↔ ↗ ↔
Multi-centre evaluation of clinical PET/MRI ↓ ↘ ↘ ↘ ↘
Multi-parametric imaging is a key driver for PET/MRI ↔ ↗ ↗ ↗ ↑
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combination of pathological validation, serial imaging, and
most importantly, by the final outcome. The aggregate
costs of arriving at a final management plan for each
strategy, combined with patient preference and final
clinical outcomes of patients, are then used to measure
cost effectiveness and cost utility.
In addition to clinical impact, a further dimension of imaging
that needs to be considered is the ability of a test to characterise
disease. This goes beyond simply finding disease and defining a
treatment course. Tests that can better stratify outcome within a
group of patients with the same type and extent of disease
receiving the same therapy can be said to provide added value.
Imaging as a predictive or prognostic biomarker is an area of
application where PET/MRI may transcend either modality alone,
while use of highly specific PET tracers andmulti-parametricMRI
may also surpass [18F]FDG-PET/CT. Related discussions can be
found in [71].
Roundtable Discussion—How to
Build and Sustain Innovation
In this session, Industry met with academia and clinical
users to address the issue of how PET/MRI can achieve its
full potential, beyond where it is today, by utilising the
myriad of tools and biological targets it already has
available. The beginning point for any innovation needs
to be good science and the ability to see the larger picture.
The industry participants reiterated that invention is not the
same as innovation and that innovation is something that
people want to adopt Band are prepared to pay for^. In the
context of healthcare, innovation was seen as Bturning
good ideas into something that can be used in the clinic^ or
as one of the panellists put it Binnovation is an invention
that creates added value^. Thus, innovation would ideally
produce better outcomes and increased access for patients
while helping to contain or decrease costs.
The key to a sustainable use of PET/MRI was seen to be
the development of expanded data analysis methods that
would provide new, multi-parametric information about
disease, rather than just providing more images to be
visually inspected. From the vendors’ perspective the three
main challenges in healthcare today are a demographic
shift towards an aging population, an underserved demand
for state-of-the-art healthcare (particularly in emerging
countries), and rising costs in existing healthcare systems.
In light of these challenges, PET/MRI today appears more
of a challenge than a solution.
As the discussion ensued, the question which arose was
whether PET/MRI had been developed to solve a particular
problem or whether it had been simply assumed that the
combination of these two high-end medical imaging
modalities would synergistically produce an innovative
device which users would be prepared to pay for.
Naturally, the answer to that question varied with the
background of the responder. Going by the definition of
innovation, panellists and attendees agreed on the potential
of PET/MRI but that, as it stands, PET/MRI cannot be
called an innovative technique quite yet, given the limited
proof of added value [6].
Summary
The topics of the Tübingen PET/MRI workshops have
evolved over the years in an attempt to identify and discuss
the most salient contemporary questions (Table 9). This
fifth workshop has shown that in oncology a clear
demarcation between [18F]FDG-PET/CT and newer studies
with non-[18F]FDG PET/MRI has emerged. Prostate cancer
imaging may well prove to be the first key application in
oncology for PET/MRI, but it remains to be seen whether
the incremental value is confined to the pelvis or can be
applied efficiently to whole-body protocols. In cardiovas-
cular disease, despite the promise and current use of both
PET and MRI in cardiovascular investigation, PET/MRI is
still seen mainly as a research tool but may be well suited
to the dedicated imaging of atherosclerotic plaque and
myocardial inflammatory processes in the future. Neuro-
science studies with PET/MRI had begun to emerge where
the contemporaneous measurement of the PET and MRI
signals are seen as essential, for example, in joint PET and
MRI functional activation studies, drug challenges, and
functional connectivity investigations but these remain,
like cardiology, largely in the domain of research. The
studies are virtually impossible to reproduce on separate
imaging systems during separate investigations.
The new areas that were discussed for the first time at
the meeting this year included infection and inflammation
imaging, functional imaging of the pancreas in diabetes,
and the emerging science of radiomics. Many of these
areas will require new approaches to data analysis and will
provide challenges for the future.
During one of the sessions the audience was posed a
series of questions related to commonly addressed aspects of
PET/MRI implementation. Subsequent to the meeting, the
questions were formalised into a survey and participants
were invited to respond (52 (43 %) did respond) to the
questions that were asked (Fig. 2) and show clearly that the
field is moving to a more sophisticated view on the use of
PET/MRI, largely for new and unique imaging applications.
It is clear that developments in closely related fields—from
radiochemistry to radiomics—will continue to allow PET/
MRI to explore new horizons well into the future to impact
on our understanding of not only the nature of human
disease but also the nature of the disease in the individual
human.
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